NanoPhoria

Still buzzing from Monday’s milestone… The response to NanoPhoria’s Series A announcement has been incredible. Thank you to everyone who reached out, shared, and celebrated with us. This is just the beginning. 👏 Grateful to be working alongside such a brilliant team: Claudio De Luca, Daniele Catalucci, Michele Iafisco, Alessio Alogna, Suman Shirodkar, Lucia Faccio, and my partner in crime for the operation David Siner. I’m also truly excited to collaborate with our new investors and partners. If you’re curious to see who’s joined the journey, check out the latest updates on our LinkedIn page. 🔗 If you missed the news, follow NanoPhoria on LinkedIn to stay updated: 👉NanoPhoria #NanoPhoria #Biotech #HeartFailure #DrugDelivery #CardiovascularResearch

Big News From NanoPhoria Today! We have secured €83.5m in what is Italy's largest ever Series A Biotech raise to further advance our lead candidate, NP-MP1, through IND-enabling studies and early clinical development. For those of you that don't already know, NP-MP1 is a first-in-class peptide that targets cardiac L-type calcium channels to improve ejection fraction for the treatment of heart failure with reduced ejection fraction (HFrEF). We would like to take this moment to extend our gratitude to everyone involved in NanoPhoria's story so far: our founders, our board, and, of course, the investors who made this round possible: XGEN Venture, Sofinnova Partners, CDP Venture Capital SGR, and Panakes Partners. We would also like to thank our unnamed investor - more on this to come soon. Keep your eyes and ears peeled for more big updates from NanoPhoria as we make strides towards treating conditions impacting tens of millions of patients worldwide. https://lnkd.in/dVWnDixi #HeartFailure #ItalianBiotech #SeriesA #NanoPhoria

We would not be here without our investors. In light of our record-breaking series A round, the team at NanoPhoria would like to highlight the efforts of Niccolò Mussi from CDP Venture Capital SGR. "The whole team at CDP Venture Capital is delighted with our investment in NanoPhoria. The company is a stand-out example of what makes Italy's biotech ecosystem so strong amongst its peers, and we look forward to supporting the company as we follow them along their journey to treat millions of patients suffering from heart failure," says Mussi. #NanoPhoria #SeriesA #ItalianBiotech #HFrEF

💪 Completing Italy's largest ever Series A round in biotech was no small feat. And at NanoPhoria, we like to show our gratitude to those that help make big things possible. In particular, we would like to thank the chair of our board, Suman Shirodkar, for her expert guidance throughout this process. In her words: "The landmark series A fundraise for Nanophoria Biosciences is a resounding endorsement of our breakthrough science and bold vision.  It has been exciting and rewarding to work alongside a determined team to create and advance our plans to convert our science into impactful medicines." #NanoPhoria #SeriesA #ItalianBiotech #HFrEF

Big News From NanoPhoria Today! We have secured €83.5m in what is Italy's largest ever Series A Biotech raise to further advance our lead candidate, NP-MP1, through IND-enabling studies and early clinical development. For those of you that don't already know, NP-MP1 is a first-in-class peptide that targets cardiac L-type calcium channels to improve ejection fraction for the treatment of heart failure with reduced ejection fraction (HFrEF). We would like to take this moment to extend our gratitude to everyone involved in NanoPhoria's story so far: our founders, our board, and, of course, the investors who made this round possible: XGEN Venture, Sofinnova Partners, CDP Venture Capital SGR, and Panakes Partners. We would also like to thank our unnamed investor - more on this to come soon. Keep your eyes and ears peeled for more big updates from NanoPhoria as we make strides towards treating conditions impacting tens of millions of patients worldwide. https://lnkd.in/dVWnDixi #HeartFailure #ItalianBiotech #SeriesA #NanoPhoria

 💡NanoPhoria was excited to sponsor #MICRO23, a lively congress that brought together pioneers in microencapsulation and biotech innovation.   🔬From inspiring talks to cutting-edge research, as a biotech startup developing an innovative drug delivery platform using micro- and nano-carriers, MICRO23 gave us the opportunity to connect with brilliant researchers, explore potential partnerships, and generate new ideas. Big thanks to the organizers and the scientific community for the inspiring exchange. #BiotechInnovation #MICRO23 #DrugDelivery #Nano

Take a look! #Nanophoria #inhalation #heartfailure #drugdelivery

Check out the latest publication by two of the founders of NanoPhoria, Daniele Catalucci and Alessio Alogna. In this work, they introduce the term "cardiovascular inhalation," a groundbreaking approach that opens new opportunities for delivering biologics directly to the heart through inhalation. This paper not only emphasizes the potential of this method but also provides valuable insights into the practical aspects of formulating such therapies, making it a significant contribution to the field. 🔗Read here: https://lnkd.in/dVtJY3WG #heartfailure #inhalationtherapy #drugdelivery #peptide #cardiovascularinnovation

One of our founders, Alessio Alogna, shared groundbreaking insights during the New Frontiers in Heart Failure Therapies session at the ESC Heart Failure 2025 Congress in Belgrade, highlighting inhalation-based nanotherapies as a promising approach for targeted heart failure treatment. #heartfailure #inhalation #nanoparticles #peptide